microRNA 196a-2 (MIR196A2)

microRNA 196a-2 is a gene-encoded, small non-coding RNA (miRNA) belonging to the Mir-196 family. In humans, it is transcribed from the MIR196A2 gene, producing a precursor that generates mature miR-196a-5p and miR-196a-3p. Mature miR-196a-2 is incorporated into the RNA-induced silencing complex (RISC), where it mediates the post-transcriptional regulation of multiple target mRNAs, including HOX gene family members and others involved in cell cycle, differentiation, and immune processes[2][4][1]. Dysregulation or genetic variation of MIR196A2 has been implicated in the pathogenesis, progression, and prognosis of numerous cancer types as well as a range of developmental and inflammatory diseases[1][3][4][5][6]. MIR196A2 variants are studied as biomarkers for clinical risk stratification and therapeutic response, although no approved drugs directly target this microRNA to date. If further disambiguation or explicit identification is needed, consult experimental databases and updated clinical trial repositories on miRNA-targeted therapies.

Other names

hsa-mir-196a-2hsa-mir-196-2MIRN196-2MIRN196A2mir-196a-2microRNA 196-2MIR196A2

Drugs or therapeutic modalities would act via modulation (inhibition or mimicry) of MIR196A2, influencing its suppression of target mRNAs or restoring altered regulatory networks in disease (especially cancer)[3][4][1]